Követo″készítmények alkalmazá sának leheto″ségei a transzplantáció immunszuppresszív terápiájában

Translated title of the contribution: Special considerations in generic substitution of immunosuppressive drugs in transplantation

A. Remport, Dávid Dankó, Zsuzsa Gerlei, Krisztina Czebe, István Kiss

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Long-term success in solid organ transplantation strongly depends on the optimal use of maintenance immunosuppressive treatment. Cyclosporin and tacrolimus are the most frequently administered immunosuppressants and they are designed to narrow therapeutic index drugs. The substitution of the branded formulation by their generic counterparts may lead to economic benefit only if equivalent clinical outcomes can be achieved. There is no published evidence to date on the guarantee of their long-term therapeutic equivalence and cases of therapeutic failures have been reported due to inadvertent drug conversion. The disadvantageous clinical consequences of a non medical, mechanistic forced switch from the original to generic formulation of tacrolimus and the estimated loss of the payer's presumed savings are presented in a kidney transplant recipient population. Special problems related to pediatric patients, drug interactions with concurrent medications and the burden of additional therapeutic drug monitoring and follow up visits are also discussed. The authors are convinced that the implementation of the European Society of Organ Transplantation guidelines on generic substitution may provide a safe way for patients and healthcare payers.

Original languageHungarian
Pages (from-to)1341-1349
Number of pages9
JournalOrvosi Hetilap
Volume153
Issue number34
DOIs
Publication statusPublished - Aug 1 2012

Fingerprint

Drug Substitution
Immunosuppressive Agents
Transplantation
Tacrolimus
Organ Transplantation
Pharmaceutical Preparations
Drug Monitoring
Therapeutics
Drug Interactions
Cyclosporine
Maintenance
Economics
Guidelines
Pediatrics
Delivery of Health Care
Kidney
Population

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Követo″készítmények alkalmazá sának leheto″ségei a transzplantáció immunszuppresszív terápiájában. / Remport, A.; Dankó, Dávid; Gerlei, Zsuzsa; Czebe, Krisztina; Kiss, István.

In: Orvosi Hetilap, Vol. 153, No. 34, 01.08.2012, p. 1341-1349.

Research output: Contribution to journalArticle

Remport, A. ; Dankó, Dávid ; Gerlei, Zsuzsa ; Czebe, Krisztina ; Kiss, István. / Követo″készítmények alkalmazá sának leheto″ségei a transzplantáció immunszuppresszív terápiájában. In: Orvosi Hetilap. 2012 ; Vol. 153, No. 34. pp. 1341-1349.
@article{f89be52c4bfb47dd8abcd4c10c44e635,
title = "K{\"o}veto″k{\'e}sz{\'i}tm{\'e}nyek alkalmaz{\'a} s{\'a}nak leheto″s{\'e}gei a transzplant{\'a}ci{\'o} immunszuppressz{\'i}v ter{\'a}pi{\'a}j{\'a}ban",
abstract = "Long-term success in solid organ transplantation strongly depends on the optimal use of maintenance immunosuppressive treatment. Cyclosporin and tacrolimus are the most frequently administered immunosuppressants and they are designed to narrow therapeutic index drugs. The substitution of the branded formulation by their generic counterparts may lead to economic benefit only if equivalent clinical outcomes can be achieved. There is no published evidence to date on the guarantee of their long-term therapeutic equivalence and cases of therapeutic failures have been reported due to inadvertent drug conversion. The disadvantageous clinical consequences of a non medical, mechanistic forced switch from the original to generic formulation of tacrolimus and the estimated loss of the payer's presumed savings are presented in a kidney transplant recipient population. Special problems related to pediatric patients, drug interactions with concurrent medications and the burden of additional therapeutic drug monitoring and follow up visits are also discussed. The authors are convinced that the implementation of the European Society of Organ Transplantation guidelines on generic substitution may provide a safe way for patients and healthcare payers.",
keywords = "cyclosporin, generic, healthcare costs, immunosuppression, tacrolimus, transplantation",
author = "A. Remport and D{\'a}vid Dank{\'o} and Zsuzsa Gerlei and Krisztina Czebe and Istv{\'a}n Kiss",
year = "2012",
month = "8",
day = "1",
doi = "10.1556/OH.2012.29429",
language = "Hungarian",
volume = "153",
pages = "1341--1349",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "34",

}

TY - JOUR

T1 - Követo″készítmények alkalmazá sának leheto″ségei a transzplantáció immunszuppresszív terápiájában

AU - Remport, A.

AU - Dankó, Dávid

AU - Gerlei, Zsuzsa

AU - Czebe, Krisztina

AU - Kiss, István

PY - 2012/8/1

Y1 - 2012/8/1

N2 - Long-term success in solid organ transplantation strongly depends on the optimal use of maintenance immunosuppressive treatment. Cyclosporin and tacrolimus are the most frequently administered immunosuppressants and they are designed to narrow therapeutic index drugs. The substitution of the branded formulation by their generic counterparts may lead to economic benefit only if equivalent clinical outcomes can be achieved. There is no published evidence to date on the guarantee of their long-term therapeutic equivalence and cases of therapeutic failures have been reported due to inadvertent drug conversion. The disadvantageous clinical consequences of a non medical, mechanistic forced switch from the original to generic formulation of tacrolimus and the estimated loss of the payer's presumed savings are presented in a kidney transplant recipient population. Special problems related to pediatric patients, drug interactions with concurrent medications and the burden of additional therapeutic drug monitoring and follow up visits are also discussed. The authors are convinced that the implementation of the European Society of Organ Transplantation guidelines on generic substitution may provide a safe way for patients and healthcare payers.

AB - Long-term success in solid organ transplantation strongly depends on the optimal use of maintenance immunosuppressive treatment. Cyclosporin and tacrolimus are the most frequently administered immunosuppressants and they are designed to narrow therapeutic index drugs. The substitution of the branded formulation by their generic counterparts may lead to economic benefit only if equivalent clinical outcomes can be achieved. There is no published evidence to date on the guarantee of their long-term therapeutic equivalence and cases of therapeutic failures have been reported due to inadvertent drug conversion. The disadvantageous clinical consequences of a non medical, mechanistic forced switch from the original to generic formulation of tacrolimus and the estimated loss of the payer's presumed savings are presented in a kidney transplant recipient population. Special problems related to pediatric patients, drug interactions with concurrent medications and the burden of additional therapeutic drug monitoring and follow up visits are also discussed. The authors are convinced that the implementation of the European Society of Organ Transplantation guidelines on generic substitution may provide a safe way for patients and healthcare payers.

KW - cyclosporin

KW - generic

KW - healthcare costs

KW - immunosuppression

KW - tacrolimus

KW - transplantation

UR - http://www.scopus.com/inward/record.url?scp=84866093383&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866093383&partnerID=8YFLogxK

U2 - 10.1556/OH.2012.29429

DO - 10.1556/OH.2012.29429

M3 - Article

C2 - 22913916

AN - SCOPUS:84866093383

VL - 153

SP - 1341

EP - 1349

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 34

ER -